Corporate
-
Perennial Leader for Venture Financings
Represent more companies that receive venture financing than any other U.S. law firm and consistently rank No. 1 for the number of company-side venture capital deals handled each year. In fact, LSEG ranked Wilson Sonsini as the top law firm by number of venture capital rounds raised in 2023 in its “Global Private Equity Legal Advisory - Full Year 2023.”
-
Ranked Among Top Capital Markets Advisors to Companies and Underwriters
We are consistently ranked by Bloomberg, Thomson Reuters, and CapitalIQ as a leading advisor to companies and underwriters based on the number of completed IPOs and equity and equity-linked offerings. Over the past 20 years, the firm has represented some of the world’s most iconic companies, including Google, LinkedIn, Twitter, and Lyft.
-
Advising on Hundreds of M&A Deals Annually
In 2023, Wilson Sonsini advised on more than 120 M&A deals that were announced and/or completed during the year, with an aggregate disclosed value of more than $60 billion. In 2022, the firm advised on more than 135 M&A deals that were announced and/or completed during the year, with an aggregate disclosed value of more than $119 billion.
Wilson Sonsini Goodrich & Rosati is the premier legal advisor to technology, life sciences, and growth enterprises worldwide, as well as the venture firms, private equity firms, and investment banks that finance them. We represent companies at every stage of development, from entrepreneurial start-ups to multibillion-dollar global corporations. The firm's attorneys collaborate across a comprehensive range of practice areas and industry groups to help the management, boards of directors, shareholders, and in-house counsel of our clients address their most pressing challenges and pursue their most promising opportunities.
Wilson Sonsini is nationally recognized for providing high-quality services to address the legal solutions required by its enterprise and financial institution clients. Our services include corporate law and governance, public and private offerings of equity and debt securities, mergers and acquisitions, joint ventures and strategic alliances, technology licensing and other intellectual property transactions, tax, employee benefits, and other corporate transactional areas.
Our clients are companies and other entities that compete in rapidly developing and innovative industries, including the biotech, communications, digital media, energy, financial services, medical devices, and software sectors.
Overview
Wilson Sonsini Goodrich & Rosati is the premier legal advisor to technology, life sciences, and growth enterprises worldwide, as well as the venture firms, private equity firms, and investment banks that finance them. We represent companies at every stage of development, from entrepreneurial start-ups to multibillion-dollar global corporations. The firm's attorneys collaborate across a comprehensive range of practice areas and industry groups to help the management, boards of directors, shareholders, and in-house counsel of our clients address their most pressing challenges and pursue their most promising opportunities.
Wilson Sonsini is nationally recognized for providing high-quality services to address the legal solutions required by its enterprise and financial institution clients. Our services include corporate law and governance, public and private offerings of equity and debt securities, mergers and acquisitions, joint ventures and strategic alliances, technology licensing and other intellectual property transactions, tax, employee benefits, and other corporate transactional areas.
Our clients are companies and other entities that compete in rapidly developing and innovative industries, including the biotech, communications, digital media, energy, financial services, medical devices, and software sectors.
Client Highlights
Wilson Sonsini Advises Forte Biosciences on Oversubscribed $53 Million Equity Financing
On November 20, 2024, biopharmaceutical company Forte Biosciences announced an oversubscribed $53 million equity financing to support the continuing clinical advancement of FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. TD Cowen acted as the lead placement agent for the financing. Guggenheim Securities provided Capital Markets Advisory services to Forte Biosciences. Chardan, Rodman & Renshaw and Brookline Capital Markets acted as co-placement managers for the financing.
Client Highlights
Wilson Sonsini Advises Investors on Zenflow’s $24 Million Series C Financing
On November 18, 2024, Zenflow, Inc., a medical device company developing a minimally invasive treatment for urinary obstruction caused by enlarged prostate, or benign prostatic hyperplasia (BPH), announced that it has closed a $24 million Series C financing round. The round included new investor Cook Medical as well as existing investors Invus Opportunities, F-Prime Capital, Medical Technology Venture Partners, and others. Wilson Sonsini Goodrich & Rosati advised Invus, F-Prime, and MedTech Venture Partners on the transaction.
The proceeds from the financing will be used to support Zenflow’s Pre-Market Approval (PMA) submission and prepare for commercialization upon FDA approval of its Spring® System, a minimally invasive treatment option for patients who suffer debilitating symptoms due to enlarged prostate.
The Wilson Sonsini team that advised Invus, F-Prime, and MedTech Venture Partners on the transaction included Jen Fang and Taylor Miller.
For more information, please see Zenflow’s news release.
The proceeds from the financing will be used to support Zenflow’s Pre-Market Approval (PMA) submission and prepare for commercialization upon FDA approval of its Spring® System, a minimally invasive treatment option for patients who suffer debilitating symptoms due to enlarged prostate.
The Wilson Sonsini team that advised Invus, F-Prime, and MedTech Venture Partners on the transaction included Jen Fang and Taylor Miller.
For more information, please see Zenflow’s news release.
Client Highlights
Wilson Sonsini Advises OneStream on Registered and Synthetic Secondary Offering
On November 18, 2024, OneStream, Inc., the leading enterprise finance management platform that modernizes the Office of the CFO by unifying core finance and operational functions, closed an underwritten public offering of 15,000,000 shares of its Class A common stock at a public offering price of $31.00 per share. Wilson Sonsini Goodrich & Rosati represented OneStream in the transaction.
Client Highlights
Wilson Sonsini Advises Upstart in Private Offering of $500 Million of Convertible Senior Notes
On November 15, 2024, Upstart Holdings, Inc. completed an offering of $500 million aggregate principal amount of 1.00% convertible senior notes due 2030 in a private transaction. The offering amount included the exercise in full of the option that Upstart had granted to the initial purchasers to purchase up to an additional $75 million of notes.
Newsletters
The Entrepreneurs Report – Q3 2024
In this latest issue of The Entrepreneurs Report, we’ve compiled a range of data on venture, convertible note, and SAFE financing transactions in which the firm was involved during the third quarter of 2024, with the objective of identifying relevant trends in activity and valuation levels for the U.S. venture capital industry in general.
Insights
Client Highlights
Wilson Sonsini Advises Forte Biosciences on Oversubscribed $53 Million Equity Financing
On November 20, 2024, biopharmaceutical company Forte Biosciences announced an oversubscribed $53 million equity financing to support the continuing clinical advancement of FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. TD Cowen acted as the lead placement agent for the financing. Guggenheim Securities provided Capital Markets Advisory services to Forte Biosciences. Chardan, Rodman & Renshaw and Brookline Capital Markets acted as co-placement managers for the financing.
Client Highlights
Wilson Sonsini Advises Investors on Zenflow’s $24 Million Series C Financing
On November 18, 2024, Zenflow, Inc., a medical device company developing a minimally invasive treatment for urinary obstruction caused by enlarged prostate, or benign prostatic hyperplasia (BPH), announced that it has closed a $24 million Series C financing round. The round included new investor Cook Medical as well as existing investors Invus Opportunities, F-Prime Capital, Medical Technology Venture Partners, and others. Wilson Sonsini Goodrich & Rosati advised Invus, F-Prime, and MedTech Venture Partners on the transaction.
The proceeds from the financing will be used to support Zenflow’s Pre-Market Approval (PMA) submission and prepare for commercialization upon FDA approval of its Spring® System, a minimally invasive treatment option for patients who suffer debilitating symptoms due to enlarged prostate.
The Wilson Sonsini team that advised Invus, F-Prime, and MedTech Venture Partners on the transaction included Jen Fang and Taylor Miller.
For more information, please see Zenflow’s news release.
The proceeds from the financing will be used to support Zenflow’s Pre-Market Approval (PMA) submission and prepare for commercialization upon FDA approval of its Spring® System, a minimally invasive treatment option for patients who suffer debilitating symptoms due to enlarged prostate.
The Wilson Sonsini team that advised Invus, F-Prime, and MedTech Venture Partners on the transaction included Jen Fang and Taylor Miller.
For more information, please see Zenflow’s news release.
Client Highlights
Wilson Sonsini Advises OneStream on Registered and Synthetic Secondary Offering
On November 18, 2024, OneStream, Inc., the leading enterprise finance management platform that modernizes the Office of the CFO by unifying core finance and operational functions, closed an underwritten public offering of 15,000,000 shares of its Class A common stock at a public offering price of $31.00 per share. Wilson Sonsini Goodrich & Rosati represented OneStream in the transaction.
Client Highlights
Wilson Sonsini Advises Upstart in Private Offering of $500 Million of Convertible Senior Notes
On November 15, 2024, Upstart Holdings, Inc. completed an offering of $500 million aggregate principal amount of 1.00% convertible senior notes due 2030 in a private transaction. The offering amount included the exercise in full of the option that Upstart had granted to the initial purchasers to purchase up to an additional $75 million of notes.
Newsletters
The Entrepreneurs Report – Q3 2024
In this latest issue of The Entrepreneurs Report, we’ve compiled a range of data on venture, convertible note, and SAFE financing transactions in which the firm was involved during the third quarter of 2024, with the objective of identifying relevant trends in activity and valuation levels for the U.S. venture capital industry in general.
Affiliated Programs
Utah Tech Week
We’re excited to be supporting partners of Utah Tech Week, coming Jan 27 - Feb 1, 2025! Utah Tech Week is a week-long, grassroots celebration of Utah’s tech and startup ecosystem. You can register at utahtechweek.com to get access to the master calendar dropping soon.
Affiliated Programs
2024 Bohemian Medical Device Summit
The 19th Annual Bohemian Medical Device Summit is an invitation-only conference for CEOs and senior executives from medical device companies. The event will provide a private and exclusive setting for networking and partnering. The agenda includes high-level panel discussions with keynotes from industry and academic leaders, as well as social networking events.
Affiliated Programs
US Expansion, Fundraising & Exit: A Masterclass for Founders, Operators and Investors
Wilson Sonsini is delighted to be partnering on a very special evening at the US Embassy. The event is a masterclass on all things US Expansion, Fundraising and Exit and idesigned to help anyone from a fund or their portfolio thinking of expanding to the US.
Affiliated Programs
Silicon Valley Leaders Forum & The State of Diabetes: Northern California
Wilson Sonsini is proud to sponsor the American Diabetes Association Leaders Forum. This year, the State of Diabetes will be headlined by a breakfast and networking session. The State of Diabetes event includes a comprehensive panel discussion led by distinguished experts offering insights into topics impacting diabetes in our community. These discussions will be a catalyst for the Leaders Forum.
Events
Affiliated Programs
Utah Tech Week
We’re excited to be supporting partners of Utah Tech Week, coming Jan 27 - Feb 1, 2025! Utah Tech Week is a week-long, grassroots celebration of Utah’s tech and startup ecosystem. You can register at utahtechweek.com to get access to the master calendar dropping soon.
Affiliated Programs
2024 Bohemian Medical Device Summit
The 19th Annual Bohemian Medical Device Summit is an invitation-only conference for CEOs and senior executives from medical device companies. The event will provide a private and exclusive setting for networking and partnering. The agenda includes high-level panel discussions with keynotes from industry and academic leaders, as well as social networking events.
Affiliated Programs
US Expansion, Fundraising & Exit: A Masterclass for Founders, Operators and Investors
Wilson Sonsini is delighted to be partnering on a very special evening at the US Embassy. The event is a masterclass on all things US Expansion, Fundraising and Exit and idesigned to help anyone from a fund or their portfolio thinking of expanding to the US.
Affiliated Programs
Silicon Valley Leaders Forum & The State of Diabetes: Northern California
Wilson Sonsini is proud to sponsor the American Diabetes Association Leaders Forum. This year, the State of Diabetes will be headlined by a breakfast and networking session. The State of Diabetes event includes a comprehensive panel discussion led by distinguished experts offering insights into topics impacting diabetes in our community. These discussions will be a catalyst for the Leaders Forum.
Sebastian Alsheimer
Partner
Sebastian Alsheimer is a corporate partner in the New York office of Wilson Sonsini Goodrich & Rosati. He is a leader of the firm’s shareholder engagement and activism practice, focusing on shareholder activism, proxy contests, corporate governance, and mergers and acquisitions.
Lester Ang
Partner
Lester Ang is a corporate and securities partner in the Palo Alto office of Wilson Sonsini, where he works with private and public technology and life sciences companies through all stages of their growth, as well as with venture capital firms and private equity firms.
Brian Appel
Partner
Brian Appel is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he practices corporate and securities law. He advises companies on general corporate matters, including formation and operation, corporate governance, debt and equity financings, mergers and acquisitions, and securities-related matters. He has assisted early-stage companies in numerous capital-raising transactions, including venture capital financings.
Megan J. Baier
Partner
Megan represents technology and life sciences clients in corporate transactional matters.
Mark Bass
Partner
Mark Bass is a partner in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where he works with public and private technology companies at all stages of growth. He also represents venture capital funds, private equity firms, and investment banks in financings and public offerings.
Mark B. Baudler
Partner
Mark is a corporate law veteran, having advised start-ups and mature public companies for more than 25 years.
Braden L. Berg
Partner
Brady L. Berg is a partner at Wilson Sonsini Goodrich & Rosati, where he focuses on corporate and securities law, including venture capital transactions, public offerings, and mergers and acquisitions with an emphasis on technology start-ups.
Steven V. Bernard
Partner
Steve has represented non-U.S. and domestic companies in U.S. IPOs, global securities offerings, cross-border M&A, and SEC compliance for more than 25 years.
Richard C. Blake
Partner
Richard has a comprehensive corporate law background, with extensive experience in public offerings.
Adam Shaun Bloom
Partner
Adam's corporate law practice focuses on complex transactions and deals involving novel structures.
People
Sebastian Alsheimer
Partner
Sebastian Alsheimer is a corporate partner in the New York office of Wilson Sonsini Goodrich & Rosati. He is a leader of the firm’s shareholder engagement and activism practice, focusing on shareholder activism, proxy contests, corporate governance, and mergers and acquisitions.
Lester Ang
Partner
Lester Ang is a corporate and securities partner in the Palo Alto office of Wilson Sonsini, where he works with private and public technology and life sciences companies through all stages of their growth, as well as with venture capital firms and private equity firms.
Brian Appel
Partner
Brian Appel is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he practices corporate and securities law. He advises companies on general corporate matters, including formation and operation, corporate governance, debt and equity financings, mergers and acquisitions, and securities-related matters. He has assisted early-stage companies in numerous capital-raising transactions, including venture capital financings.
Megan J. Baier
Partner
Megan represents technology and life sciences clients in corporate transactional matters.
Mark Bass
Partner
Mark Bass is a partner in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where he works with public and private technology companies at all stages of growth. He also represents venture capital funds, private equity firms, and investment banks in financings and public offerings.
Mark B. Baudler
Partner
Mark is a corporate law veteran, having advised start-ups and mature public companies for more than 25 years.
Braden L. Berg
Partner
Brady L. Berg is a partner at Wilson Sonsini Goodrich & Rosati, where he focuses on corporate and securities law, including venture capital transactions, public offerings, and mergers and acquisitions with an emphasis on technology start-ups.
Steven V. Bernard
Partner
Steve has represented non-U.S. and domestic companies in U.S. IPOs, global securities offerings, cross-border M&A, and SEC compliance for more than 25 years.
Richard C. Blake
Partner
Richard has a comprehensive corporate law background, with extensive experience in public offerings.
Adam Shaun Bloom
Partner
Adam's corporate law practice focuses on complex transactions and deals involving novel structures.
Related Practices
- Capital Markets
- Corporate Governance
- Corporate Life Sciences
- Emerging Companies and Venture Capital
- Employee Benefits and Compensation
- Energy and Climate Solutions
- Finance and Structured Finance
- Fund Formation
- Greater China
- Israel
- Latin America
- Life Sciences Business Advisory Practice
- Mergers & Acquisitions
- Private Equity
- Public Company Representation
- Real Estate
- Restructuring
- Shareholder Engagement and Activism
- Special Purpose Acquisition Companies (SPACs)
- Tax
- U.S. Expansion
Recent Insights
Client Highlights
Wilson Sonsini Advises Forte Biosciences on Oversubscribed $53 Million Equity Financing
On November 20, 2024, biopharmaceutical company Forte Biosciences announced an oversubscribed $53 million equity financing to support the continuing clinical advancement of FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. TD Cowen acted as the lead placement agent for the financing. Guggenheim Securities provided Capital Markets Advisory services to Forte Biosciences. Chardan, Rodman & Renshaw and Brookline Capital Markets acted as co-placement managers for the financing.
Learn More
Client Highlights
Wilson Sonsini Advises Investors on Zenflow’s $24 Million Series C Financing
On November 18, 2024, Zenflow, Inc., a medical device company developing a minimally invasive treatment for urinary obstruction caused by enlarged prostate, or benign prostatic hyperplasia (BPH), announced that it has closed a $24 million Series C financing round. The round included new investor Cook Medical as well as existing investors Invus Opportunities, F-Prime Capital, Medical Technology Venture Partners, and others. Wilson Sonsini Goodrich & Rosati advised Invus, F-Prime, and MedTech Venture Partners on the transaction.
The proceeds from the financing will be used to support Zenflow’s Pre-Market Approval (PMA) submission and prepare for commercialization upon FDA approval of its Spring® System, a minimally invasive treatment option for patients who suffer debilitating symptoms due to enlarged prostate.
The Wilson Sonsini team that advised Invus, F-Prime, and MedTech Venture Partners on the transaction included Jen Fang and Taylor Miller.
For more information, please see Zenflow’s news release.
The proceeds from the financing will be used to support Zenflow’s Pre-Market Approval (PMA) submission and prepare for commercialization upon FDA approval of its Spring® System, a minimally invasive treatment option for patients who suffer debilitating symptoms due to enlarged prostate.
The Wilson Sonsini team that advised Invus, F-Prime, and MedTech Venture Partners on the transaction included Jen Fang and Taylor Miller.
For more information, please see Zenflow’s news release.
Learn More
Recent Events
Affiliated Programs
Utah Tech Week
We’re excited to be supporting partners of Utah Tech Week, coming Jan 27 - Feb 1, 2025! Utah Tech Week is a week-long, grassroots celebration of Utah’s tech and startup ecosystem. You can register at utahtechweek.com to get access to the master calendar dropping soon.
Learn More
Newsletters
2024 Mid-Year Technology and Life Sciences PIPE and RDO Report
Wilson Sonsini Goodrich & Rosati is pleased to present the 2024 Mid-Year Technology and Life Sciences PIPE and RDO Report, analyzing 124 private investments in public equity (PIPEs) and registered direct offerings (RDOs) by U.S.-based tech and life science companies between January 1 and June 30, 2024.
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2024 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.